<DOC>
	<DOCNO>NCT02506946</DOCNO>
	<brief_summary>This project focus at-risk adolescent young adult population may gain long-term health benefit detection risk factor young age . The primary aim proposal : 1 ) To observe whether adolescent young adult Polycystic Ovary Syndrome ( PCOS ) likely elevate liver fat ( &gt; /=4.8 % ) control study liver fat deposition measure magnetic resonance spectroscopy ( MRS ) ; 2 ) To assess association percentage liver fat biomarkers Non-alcoholic fatty liver disease ( NAFLD ) , dyslipidemia , insulin resistance body composition PCOS control . In proposed study , 40 adolescent young adult PCOS 40 age-comparable control subject evaluate metabolic disturbance elevate liver fat use noninvasive state-of-the-art technique include MRI , dual-energy x-ray absorptiometry oral glucose tolerance test order fully assess metabolic body composition difference group . This research proposal represent critical step understand metabolic cardiovascular comorbidities PCOS relationship NAFLD . The investigator hop use result generate research proposal order lay groundwork prevention treatment metabolic disorder adolescent PCOS . The overarch goal decrease prevent lifelong morbidity associate common disorder .</brief_summary>
	<brief_title>NAFLD Adolescents Young Adults With PCOS</brief_title>
	<detailed_description>PCOS common condition frequently present adolescence young adulthood define presence hyperandrogenism ovulatory dysfunction . Affected individual increase risk insulin resistance , NAFLD dyslipidemia , feature associate metabolic syndrome , major public health concern . The association PCOS insulin resistance dyslipidemia extensively describe ; however , association NAFLD recently note superficially study adolescent young adult . Additionally , yet fully elucidate seemingly healthy nonobese adolescent PCOS predispose insulin resistance related complication . The susceptibility certain PCOS patient develop NAFLD theorize due follow potentiating factor : insulin resistance , hyperandrogenemia , genetic predisposition .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>All : Healthy ; 14 25 year ; least 2 year postmenarche PCOS : Clinical hyperandrogenism and/or hyperandrogenemia , menstrual dysfunction ( oligomenorrhea amenorrhea ) exclusion know disorder . PCOS diagnose use NIH 1990 criterion . Controls : Regular menses ; clinical hyperandrogenism and/or hyperandrogenemia Past present history medical disorder medication know affect body composition , insulin secretion sensitivity , growth hormone ( GH ) insulinlike growth factor 1 ( IGF1 ) axis ( eg steroid hormone thyroid replacement ) . History current past pregnancy Hormonal contraceptive metformin use within 3 month enrollment Nonclassical congenital adrenal hyperplasia</criteria>
	<gender>Female</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Polycystic Ovary Syndrome</keyword>
	<keyword>Non-Alcoholic Fatty Liver Disease</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Young Women</keyword>
	<keyword>MRI</keyword>
	<keyword>MRS</keyword>
	<keyword>DXA</keyword>
	<keyword>Hirsutism</keyword>
	<keyword>Amenorrhea</keyword>
	<keyword>Metabolic syndrome</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Percentage liver fat</keyword>
</DOC>